The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Eniluracil     5-ethynyl-1H-pyrimidine-2,4- dione

Synonyms: Compound 776C, CHEMBL355200, GW-776, GEO-02731, CHEBI:383293, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Eniluracil

  • PATIENTS AND METHODS: Patients who were to undergo primary colorectal tumor resection received oral eniluracil 10 mg/m(2) twice daily for 3 days before surgery [1].
  • Patients received oral 5-FU 1.0 mg/m(2) with eniluracil 10 mg/m(2), both given twice daily for the first 28 days of each 35-day cycle, continuing until disease progression or unmanageable toxicity [2].
  • The primary objective of this study was to estimate the objective tumor response rate of orally administered eniluracil and 5-FU in the treatment of anthracycline- and taxane-resistant advanced breast cancer [3].
  • Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer [4].
  • With eniluracil, tumor standardized uptake values ([activity/g]/[injected activity/g body weight]) increased from 0.72 +/- 0.06 (mean +/- SEM; n = 6) to 1.57 +/- 0.20 (n = 12; P < 0.01), and tumor uptake increased by factors of 2 or more relative to plasma (P < 0.05) and bone, liver, and kidney (P < 0.01) [5].

High impact information on Eniluracil


Chemical compound and disease context of Eniluracil


Biological context of Eniluracil


Anatomical context of Eniluracil


Associations of Eniluracil with other chemical compounds


Gene context of Eniluracil


Analytical, diagnostic and therapeutic context of Eniluracil


  1. Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors. Ahmed, F.Y., Johnston, S.J., Cassidy, J., O'Kelly, T., Binnie, N., Murray, G.I., van Gennip, A.H., Abeling, N.G., Knight, S., McLeod, H.L. J. Clin. Oncol. (1999) [Pubmed]
  2. Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study. Smith, I.E., Johnston, S.R., O'Brien, M.E., Hickish, T.F., de Boer, R.H., Norton, A., Cirkel, D.T., Barton, C.M. J. Clin. Oncol. (2000) [Pubmed]
  3. Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer. Rivera, E., Sutton, L., Colwell, B., Graham, M., Frye, D., Somerville, M., Conklin, H.S., McGuirt, C., Levin, J., Hortobagyi, G.N. J. Clin. Oncol. (2002) [Pubmed]
  4. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Humerickhouse, R.A., Dolan, M.E., Haraf, D.J., Brockstein, B., Stenson, K., Kies, M., Sulzen, L., Ratain, M.J., Vokes, E.E. Clin. Cancer Res. (1999) [Pubmed]
  5. Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics. Bading, J.R., Alauddin, M.M., Fissekis, J.D., Shahinian, A.H., Joung, J., Spector, T., Conti, P.S. J. Nucl. Med. (2000) [Pubmed]
  6. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Saleem, A., Yap, J., Osman, S., Brady, F., Suttle, B., Lucas, S.V., Jones, T., Price, P.M., Aboagye, E.O. Lancet (2000) [Pubmed]
  7. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. Schilsky, R.L., Levin, J., West, W.H., Wong, A., Colwell, B., Thirlwell, M.P., Ansari, R.H., Bell, W.N., White, R.L., Yates, B.B., McGuirt, P.V., Pazdur, R. J. Clin. Oncol. (2002) [Pubmed]
  8. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. Baker, S.D., Diasio, R.B., O'Reilly, S., Lucas, V.S., Khor, S.P., Sartorius, S.E., Donehower, R.C., Grochow, L.B., Spector, T., Hohneker, J.A., Rowinsky, E.K. J. Clin. Oncol. (2000) [Pubmed]
  9. Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors. Grem, J.L., Harold, N., Shapiro, J., Bi, D.Q., Quinn, M.G., Zentko, S., Keith, B., Hamilton, J.M., Monahan, B.P., Donavan, S., Grollman, F., Morrison, G., Takimoto, C.H. J. Clin. Oncol. (2000) [Pubmed]
  10. A dose-escalating study of oral eniluracil/5-fluorouracil plus oxaliplatin in patients with advanced gastrointestinal malignancies. Yip, D., Karapetis, C., Strickland, A.H., Steer, C., Holford, C., Knight, S., Harper, P. Ann. Oncol. (2003) [Pubmed]
  11. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. Baker, S.D., Khor, S.P., Adjei, A.A., Doucette, M., Spector, T., Donehower, R.C., Grochow, L.B., Sartorius, S.E., Noe, D.A., Hohneker, J.A., Rowinsky, E.K. J. Clin. Oncol. (1996) [Pubmed]
  12. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. Porter, D.J., Chestnut, W.G., Merrill, B.M., Spector, T. J. Biol. Chem. (1992) [Pubmed]
  13. Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. Ochoa, L., Hurwitz, H.I., Wilding, G., Cohen, D., Thomas, J.P., Schwartz, G., Monroe, P., Petros, W.P., Ertel, V.P., Hsieh, A., Hoffman, C., Drengler, R., Magnum, S., Rowinsky, E.K. Ann. Oncol. (2000) [Pubmed]
  14. 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Spector, T., Harrington, J.A., Porter, D.J. Biochem. Pharmacol. (1993) [Pubmed]
  15. Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. Rothenberg, M.L., Benedetti, J.K., Macdonald, J.S., Seay, T.E., Neubauer, M.A., George, C.S., Tanaka, M.S., Giguere, J.K., Pruitt, B.T., Abbruzzese, J.L. Ann. Oncol. (2002) [Pubmed]
  16. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. Cao, S., Baccanari, D.P., Joyner, S.S., Davis, S.T., Rustum, Y.M., Spector, T. Cancer Res. (1995) [Pubmed]
  17. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Meropol, N.J., Niedzwiecki, D., Hollis, D., Schilsky, R.L., Mayer, R.J. Cancer (2001) [Pubmed]
  18. Validation of fluorouracil metabolite analysis in excised tumor. Lability of anabolites. Bading, J.R., Shahinian, A.H., Paff, M.T., Yoo, P.B., Hsia, D.W. Biochem. Pharmacol. (2000) [Pubmed]
  19. 5-ethynyl-2(1H)-pyrimidinone: aldehyde oxidase-activation to 5-ethynyluracil, a mechanism-based inactivator of dihydropyrimidine dehydrogenase. Porter, D.J., Harrington, J.A., Almond, M.R., Lowen, G.T., Zimmerman, T.P., Spector, T. Biochem. Pharmacol. (1994) [Pubmed]
  20. alpha-fluoro-beta-alanine: effects on the antitumor activity and toxicity of 5-fluorouracil. Cao, S., Baccanari, D.P., Rustum, Y.M., Davis, S.T., Tansik, R.L., Porter, D.J., Spector, T. Biochem. Pharmacol. (2000) [Pubmed]
  21. Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. Benson, A.B., Mitchell, E., Abramson, N., Klencke, B., Ritch, P., Burnhan, J.P., McGuirt, C., Bonny, T., Levin, J., Hohneker, J. Ann. Oncol. (2002) [Pubmed]
  22. Pharmacology of fluorinated pyrimidines: eniluracil. Baker, S.D. Investigational new drugs. (2000) [Pubmed]
  23. A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. Czito, B.G., Hong, T.J., Cohen, D.P., Tyler, D.S., Lee, C.G., Anscher, M.S., Ludwig, K.A., Seigler, H.F., Mantyh, C., Morse, M.A., Lockhart, A.C., Petros, W.P., Honeycutt, W., Spector, N.L., Ertel, P.J., Mangum, S.G., Hurwitz, H.I. Int. J. Radiat. Oncol. Biol. Phys. (2004) [Pubmed]
  24. A National Cancer Institute of Canada clinical trials group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer. Knowling, M., Browman, G., Siu, L., Khoo, K., Cooke, A., Tannock, I., Klaassen, D., Cripps, C., Goss, G., Matthews, S., Clarke, R., Seymour, L. Ann. Oncol. (2001) [Pubmed]
  25. Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. Shepard, D.R., Mani, S., Kastrissios, H., Learned-Coughlin, S., Smith, D., Ertel, P., Magnum, S., Janisch, L., Fleming, G.F., Schilsky, R.L., Ratain, M.J. Cancer Chemother. Pharmacol. (2002) [Pubmed]
WikiGenes - Universities